TP53 and B-cell chronic lymphocytic leukemia: The main goal of this study was to test the possibility to use PEITC as a potential agent to effectively eliminate CLL cells with loss of p53, using both in vitro assay with primary leukemia cells isolated from CLL patients with 17p-deletion and in vivo test in a CLL mouse model with TCL1-Tg:p53−/− genotype [10].